

Regioselective construction of polysubstituted phenols from Baylis–Hillman adducts via formal [4+2] annulation strategy

Seung Chan Kim,^a Hyun Seung Lee,^a Young Ju Lee^b and Jae Nyong Kim^{a,*}

^aDepartment of Chemistry and Institute of Basic Science, Chonnam National University, Gwangju 500-757, Republic of Korea

^bKorea Basic Science Institute, Gwangju branch, Gwangju 500-757, Republic of Korea

Received 28 April 2006; revised 1 June 2006; accepted 2 June 2006

Available online 27 June 2006

Abstract—Polysubstituted phenol derivatives were synthesized regioselectively starting from the Baylis–Hillman adducts via the formal [4+2] annulation protocol as the key step.


© 2006 Elsevier Ltd. All rights reserved.

Recently, we reported the synthesis of polysubstituted benzenes starting from the Baylis–Hillman adducts.¹ These valuable compounds were prepared from the Baylis–Hillman acetates of alkyl vinyl ketone by the sequential S_N2' reaction with primary nitroalkane, Michael addition, aldol condensation, elimination of HNO₂, and the final aromatization process (Scheme 1).¹ In the reaction, the modified Baylis–Hillman derivative with nitroalkane served as a four-carbon component and the Michael acceptor as a two-carbon unit. During the projects we reasoned that we could synthesize polysubstituted phenol derivatives by using a similar protocol when we used the Baylis–Hillman adducts of methyl acrylate.²

Due to the importance of phenol derivatives in pharmacologically important molecules^{3,5} and their usefulness as synthetic intermediates, much attention has been focused on their synthesis.^{3–5} A variety of methods have been examined including palladium-catalyzed enyne–diyne cross-benzannulation,^{3b} cycloaddition of Fisher carbenes with alkynes,^{3c} stepwise construction method

of benzene ring of phenol by condensation reaction as the key reaction.^{3a,d,4}


In order to examine the feasibility for the construction of polysubstituted phenol derivatives, we made **2a** from Baylis–Hillman acetate of methyl acrylate **1a** and nitroethane by following the previous method^{1,6} and examined the reaction with methyl vinyl ketone (**3a**) as shown in Scheme 2. We used DBU as the base for the Michael addition and obtained the desired product **4a** in excellent yield (97%).⁷ However, the following aldol-type cyclization did not occur under the influence of DBU. Thus we used potassium *tert*-butoxide in THF conditions and obtained **5a** in 69% yield.⁷ This compound **5a** must be formed via the successive aldol-type cyclization of **4a**, followed by enolization. During the conversion of **4a** into **5a** we observed the formation of trace amount of phenol derivative **6a** (4%); however, the amount of **6a** was not increased by elevating the reaction temperature for long time. The final step, elimination of HNO₂ and concomitant formal 1,3-hydrogen shift, was conducted with DBU again to produce **6a** in 62% yield.⁷



Scheme 1.

Keywords: Phenols; Baylis–Hillman adducts; [4+2] Annulation; Regioselective.

* Corresponding author. Tel.: +82 62 530 3381; fax: +82 62 530 3389; e-mail: kimjn@chonnam.ac.kr



Scheme 2.

With the optimized reaction conditions, we carried out the synthesis of polysubstituted phenols **6b–f** and the results are summarized in Table 1. We used Baylis–Hillman derivatives **2a–d** as the four-carbon unit and Michael acceptors **3a–d** as the two-carbon component.

As shown, the whole reactions proceeded similarly irrespective of the differences of substrates. In all cases the Michael addition reaction showed high yields of products **4a–f** (72–97%). The next aldol-type (entries 1 and 2) or Dieckmann (entries 3–6) condensation occurred


Table 1. Synthesis of polysubstituted phenols

Entry	Substrate	Michael acceptor	Intermediate 4 (%) ^a	Cyclohexene 5 (%) ^b	Phenol 6 (%) ^c
1		MVK (3a)	 4a (97)	 5a (69)	 6a (62)
2	2a	EVK (3b)	 4b (95)	 5b (68)	 6b (44)
3	2a	Methyl acrylate (3c)	 4c (83)	 5c (67)	 6c (76)
4		Ethyl acrylate (3d)	 4d (72)	 5d (63)	 6d (71)
5		3c	 4e (82)	 5e (71)	 6e (47)
6		3c	 4f (74)	 5f (66)	 6f (56)


^a Conditions: **2** (1.0 equiv), **3** (1.1 equiv), DBU (1.1 equiv), CH_3CN , rt, 30–180 min.

^b Conditions: **4** (1.0 equiv), $t\text{-BuOK}$ (1.2 equiv), THF, rt, 1–5 h.

^c Conditions: **5** (1.0 equiv), DBU (2.0 equiv), CH_3CN (or THF), reflux, 5–29 h.



Scheme 3.



Scheme 4.

in similar yields (63–71%). But, the yields of final elimination of nitrous acid and aromatization stage were much different. The yields of **6b**, **6e**, and **6f** were relatively low.

The reaction of the Michael addition product **4g** was also examined (Scheme 3). This compound **4g** was prepared by the reaction of **2a** and **3d** in 82% yield. When **4g** was treated with *t*-BuOK, we found the formation of **5c** and **5d** (1:2) in 65% yield. Compound **5c** must be produced via the transesterification process by the methoxide ion, which was generated during the Dieckmann cyclization of **4g**. The reaction of **2a** and acrylonitrile (**3e**) gave **4h** in 72% yield. However, the cyclization of **4h** under various reaction conditions failed, unfortunately (Scheme 4).

In summary, we disclosed the facile and regioselective synthesis of polysubstituted phenol derivatives starting from the Baylis–Hillman adducts via the formal [4+2] annulation protocol as the key step.

Acknowledgments

This work was supported by the Korea Research Foundation Grant funded by the Korean Government (MOEHRD, KRF-2005-041-C00248). Spectroscopic data was obtained from the Korea Basic Science Institute, Gwangju branch.

References and notes

- (a) Lee, M. J.; Lee, K. Y.; Park, D. Y.; Kim, J. N. *Tetrahedron* **2006**, *62*, 3128; (b) Lee, M. J.; Lee, K. Y.; Gowrisankar, S.; Kim, J. N. *Tetrahedron Lett.* **2006**, *47*, 1355.
- For our recent publications on the chemical transformations of Baylis–Hillman adducts, see: (a) Lee, K. Y.; Gowrisankar, S.; Kim, J. N. *Bull. Korean Chem. Soc.* **2005**, *26*, 1481; (b) Park, D. Y.; Lee, M. J.; Kim, T. H.; Kim, J. N. *Tetrahedron Lett.* **2005**, *46*, 8799; (c) Lee, M. J.; Park, D. Y.; Lee, K. Y.; Kim, J. N. *Tetrahedron Lett.* **2006**, *47*, 1833; (d) Lee, K. Y.; Kim, S. C.; Kim, J. N. *Tetrahedron Lett.* **2006**, *47*, 977; (e) Kim, J. N.; Lee, K. Y. *Curr. Org. Chem.* **2002**, *6*, 627.
- For the synthesis of polysubstituted phenol derivatives, see: (a) Nakaike, Y.; Kamijo, Y.; Mori, S.; Tamura, M.; Nishiwaki, N.; Ariga, M. *J. Org. Chem.* **2005**, *70*, 10169; (b) Gevorgyan, V.; Quan, L. G.; Yamamoto, Y. *J. Org. Chem.* **1998**, *63*, 1244; (c) Barluenga, J.; Aznar, F.; Gutierrez, I.; Martin, A.; Garcia-Granda, S.; Llorca-Baragano, M. A. *J. Am. Chem. Soc.* **2000**, *122*, 1314; (d) Poly, W.; Schomburg, D.; Hoffmann, H. M. R. *J. Org. Chem.* **1988**, *53*, 3701; (e) Fukuhara, K.; Takayama, Y.; Sato, F. *J. Am. Chem. Soc.* **2003**, *125*, 6884; (f) Padwa, A.; Dimitroff, M.; Waterson, A. G.; Wu, T. *J. Org. Chem.* **1997**, *62*, 4088; (g) Kobayashi, S.; Moriwaki, M.; Hachiya, I. *Tetrahedron Lett.* **1996**, *37*, 2053; (h) Cimarelli, C.; Palmieri, G. *Tetrahedron* **1998**, *54*, 15711.
- Kim, J. N.; Im, Y. J.; Kim, J. M. *Tetrahedron Lett.* **2002**, *43*, 6597.
- For the usefulness of phenol derivatives as synthetic intermediates, see: (a) Simaan, S.; Siegel, J. S.; Biali, S. E. *J. Org. Chem.* **2003**, *68*, 3699; (b) Crisp, G. T.; Turner, P. D. *Tetrahedron* **2000**, *56*, 407; (c) Caruso, A. J.; Lee, J. L. *J. Org. Chem.* **1997**, *62*, 1058; (d) Brigati, G.; Lucarini, M.; Mugnaini, V.; Pedulli, G. F. *J. Org. Chem.* **2002**, *67*, 4828; (e) Gobbi, S.; Rampa, A.; Bisi, A.; Belluti, F.; Piazzi, L.; Valenti, P.; Caputo, A.; Zampiron, A.; Carrara, M. *J. Med. Chem.* **2003**, *46*, 3662; (f) Leahy, J. J. J.; Golding, B. T.; Griffin, R. J.; Hardcastle, I. R.; Richardson, C.; Rigoreau, L.; Smith, G. C. M. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 6083; (g) Fougereuse, A.; Gonzalez, E.; Brouillard, R. *J. Org. Chem.* **2000**, *65*, 583; (h) Klymchenko, A. S.; Ozturk, T.; Pivovarenko, V. G.; Demchenko, A. P. *Tetrahedron Lett.* **2001**, *42*, 7967; (i) Horino, Y.; Naito, M.; Kimura, M.; Tanaka, S.; Tamaru, Y. *Tetrahedron Lett.* **2001**, *42*, 3113; (j) Rao, M. L. N.; Houjou, H.; Hiratani, K. *Tetrahedron Lett.* **2001**, *42*, 8351; (k) Perez-Serrano, L.; Blanco-Urgoiti, J.; Casarrubios, L.; Dominguez, G.; Perez-Castells, J. *J. Org. Chem.* **2000**, *65*, 3513; (l) Ruchirawat, S.; Mutarapat, T. *Tetrahedron Lett.* **2001**, *42*, 1205.
- Synthesis of starting materials, see: Kim, J. M.; Im, Y. J.; Kim, T. H.; Kim, J. N. *Bull. Korean Chem. Soc.* **2002**, *23*, 657.
- Synthesis of 4a* (Typical procedure): To a stirred mixture of **2a**⁶ (498 mg, 2.0 mmol) and methyl vinyl ketone (**3a**, 154 mg, 2.2 mmol) in CH₃CN (5 mL) was added DBU (335 mg, 2.2 mmol) and stirred for further 30 min at room temperature. After the usual aqueous extractive workup with ether and column chromatographic purification process (hexanes/EtOAc, 5:1), we obtained **4a** as a colorless oil, 619 mg (97%). The other compounds were synthesized analogously and the spectroscopic data are as follows.

Compound **4a**: (30 min, 97%); colorless oil; IR (CH₂Cl₂) 1716, 1632, 1539, 1436 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.33 (s, 3H), 1.81–1.92 (m, 1H), 2.04 (s, 3H), 2.13–2.25 (m, 3H), 3.26 (d, *J* = 14.4 Hz, 1H), 3.38 (d, *J* = 14.4 Hz, 1H), 3.78 (s, 3H), 7.27–7.29 (m, 2H), 7.32–7.44 (m, 3H), 7.91 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 21.79, 29.80, 32.62, 35.11, 37.84, 52.17, 90.12, 127.74, 128.42, 128.62, 128.78, 135.02, 143.76, 168.06, 206.15; ESIMS *m/z* 320 (M⁺+H).

Compound **4b**: (30 min, 95%); colorless oil; IR (CH₂Cl₂) 1716, 1631, 1539, 1442 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.00 (t, *J* = 7.2 Hz, 3H), 1.32 (s, 3H), 1.84–1.94 (m, 1H), 2.15–2.23 (m, 3H), 2.31 (q, *J* = 7.2 Hz, 2H), 3.26 (d, *J* = 14.7 Hz, 1H), 3.38 (d, *J* = 14.7 Hz, 1H), 3.78 (s, 3H), 7.27–7.43 (m, 5H), 7.91 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 7.65, 21.73, 32.72, 35.23, 35.81, 36.49, 52.15, 90.20, 127.76, 128.43, 128.60, 128.75, 135.02, 143.72, 168.06, 208.93.

Compound **4c**: (30 min, 83%); colorless oil; IR (CH₂Cl₂) 1732, 1716, 1631, 1543, 1439 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.35 (s, 3H), 1.84–1.94 (m, 1H), 2.03–2.22 (m, 2H), 2.27–2.37 (m, 1H), 3.25 (d, *J* = 14.7 Hz, 1H), 3.38 (d, *J* = 14.7 Hz, 1H), 3.63 (s, 3H), 3.79 (s, 3H), 7.26–7.29 (m, 2H), 7.31–7.44 (m, 3H), 7.92 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 21.43, 28.63, 33.95, 35.47, 51.78, 52.19, 89.96, 127.60, 128.41, 128.67, 128.77, 134.98, 143.92, 168.04, 172.41.

Compound **4d**: (30 min, 72%); colorless oil; IR (CH₂Cl₂) 1733, 1715, 1632, 1541, 1446 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.21 (t, *J* = 7.2 Hz, 3H), 1.33 (t, *J* = 7.2 Hz, 3H), 1.35 (s, 3H), 1.84–1.93 (m, 1H), 2.01–2.22 (m, 2H), 2.28–2.37 (m, 1H), 3.26 (d, *J* = 14.7 Hz, 1H), 3.38 (d, *J* = 14.7 Hz, 1H), 4.08 (q, *J* = 7.2 Hz, 2H), 4.24 (q, *J* = 7.2 Hz, 2H), 7.27–7.43 (m, 5H), 7.92 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.90, 13.97, 21.31, 28.78, 33.88, 35.36, 60.50, 61.26, 89.89, 127.87, 128.31, 128.47, 128.64, 134.99, 143.44, 167.44, 171.81.

Compound **4e**: (60 min, 82%); white solid, mp 78–80 °C; IR (CH₂Cl₂) 1738, 1712, 1539, 1492, 1446 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.62 (t, *J* = 7.5 Hz, 3H), 1.65–1.77 (m, 1H), 1.81–1.94 (m, 1H), 1.97–2.23 (m, 4H), 3.26 (s, 2H), 3.64 (s, 3H), 3.78 (s, 3H), 7.26–7.29 (m, 2H), 7.31–7.43 (m, 3H), 7.88 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 7.88, 28.20, 28.43, 29.19, 32.20, 51.74, 52.16, 93.25, 127.89, 128.40, 128.57, 128.74, 135.02, 143.52, 168.11, 172.44.

Compound **4f**: (180 min, 74%); colorless oil; IR (CH₂Cl₂) 1739, 1720, 1635, 1539, 1439 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.75 (t, *J* = 7.2 Hz, 3H), 0.81–0.94 (m, 2H), 1.12 (quintet, *J* = 7.2 Hz, 2H), 1.57–1.67 (m, 1H), 1.73–1.84 (m, 1H), 1.96–2.25 (m, 4H), 3.27 (s, 2H), 3.64 (s, 3H), 3.77 (s, 3H), 7.27–7.43 (m, 5H), 7.87 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.60, 22.64, 25.60, 28.50, 29.84, 32.59, 34.92, 51.75, 52.16, 92.85, 127.92, 128.39, 128.58, 128.75, 135.05, 143.38, 168.11, 172.45.

Compound **4g**: (30 min, 82%); colorless oil; IR (CH₂Cl₂) 1720, 1631, 1543, 1442 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.22 (t, *J* = 7.2 Hz, 3H), 1.35 (s, 3H), 1.84–1.94 (m, 1H), 2.02–2.21 (m, 2H), 2.27–2.37 (m, 1H), 3.25 (d, *J* = 14.7 Hz, 1H), 3.38 (d, *J* = 14.7 Hz, 1H), 3.79 (s, 3H), 4.08 (q, *J* = 7.2 Hz, 2H), 7.27–7.30 (m, 2H), 7.31–7.43 (m, 3H), 7.92 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 14.08, 21.39, 28.88, 33.96, 35.52, 52.17, 60.66, 89.99, 127.61, 128.41, 128.65, 128.76, 134.97, 143.87, 168.03, 171.95.

Compound **4h**: (30 min, 72%); colorless oil; IR (CH₂Cl₂) 2251, 1714, 1632, 1541, 1494, 1445 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.41 (s, 3H), 1.86–1.96 (m, 1H), 2.13–2.19 (m, 2H), 2.31–2.41 (m, 1H), 3.27 (d, *J* = 14.4 Hz, 1H), 3.37 (d, *J* = 14.4 Hz, 1H), 3.81 (s, 3H), 7.27–7.29 (m, 2H), 7.35–7.46 (m, 3H), 7.97 (s, 1H); ¹³C NMR (CDCl₃,

75 MHz) δ 12.44, 21.84, 34.08, 34.96, 52.37, 89.47, 118.24, 126.89, 128.29, 128.95, 128.99, 134.73, 144.55, 167.81.

Synthesis of 5a (Typical procedure): To a stirred mixture of **4a** (319 mg, 1.0 mmol) in THF (3 mL) was added *t*-BuOK (135 mg, 1.2 mmol) and the reaction mixture was stirred at room temperature for 2 h. After the usual aqueous extractive workup with ether and column chromatographic purification process (hexanes/EtOAc, 7:1), we obtained **5a** as a white solid, 199 mg (69%). The other compounds were synthesized analogously and the spectroscopic data are as follows.

Compound **5a**: (2 h, 69%); white solid, mp 173–174 °C; IR (KBr) 2900, 1621, 1534, 1446, 1418 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.65 (s, 3H), 2.28 (s, 3H), 2.81 (d, *J* = 15.9 Hz, 1H), 2.96 (d, *J* = 15.9 Hz, 1H), 3.38 (d, *J* = 15.9 Hz, 1H), 3.56 (d, *J* = 15.9 Hz, 1H), 7.33–7.45 (m, 5H), 7.76 (s, 1H), 15.85 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 26.03, 26.19, 34.76, 35.81, 85.90, 103.79, 126.65, 128.56, 128.65, 129.63, 135.30, 136.19, 169.52, 200.91; ESIMS *m/z* 288 (M⁺+H). Anal. Calcd for C₁₆H₁₇NO₄: C, 66.89; H, 5.96; N, 4.88. Found: C, 66.95; H, 6.05; N, 4.75.

Compound **5b**: (1 h, 68%); white solid, mp 135–137 °C; IR (KBr) 2980, 2903, 1624, 1577, 1535, 1446, 1414, 1342 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.18 (t, *J* = 7.2 Hz, 3H), 1.64 (s, 3H), 2.48–2.70 (m, 2H), 2.80 (d, *J* = 15.9 Hz, 1H), 2.95 (d, *J* = 15.9 Hz, 1H), 3.38 (d, *J* = 15.9 Hz, 1H), 3.55 (d, *J* = 15.9 Hz, 1H), 7.32–7.45 (m, 5H), 7.74 (s, 1H), 15.81 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 8.03, 26.06, 31.65, 34.14, 35.79, 85.91, 103.36, 126.69, 128.55 (2C), 129.60, 135.39, 135.79, 168.51, 204.23. Anal. Calcd for C₁₇H₁₉NO₄: C, 67.76; H, 6.36; N, 4.65. Found: C, 67.65; H, 6.25; N, 4.63.

Compound **5c**: (4 h, 67%); white solid, mp 144–146 °C; IR (KBr) 3024, 2958, 2897, 1655, 1616, 1589, 1539, 1442, 1346 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.61 (s, 3H), 2.74 (d, *J* = 16.5 Hz, 1H), 2.93 (d, *J* = 15.6 Hz, 1H), 3.35 (d, *J* = 16.5 Hz, 1H), 3.52 (d, *J* = 15.6 Hz, 1H), 3.84 (s, 3H), 7.30–7.44 (m, 5H), 7.60 (s, 1H), 12.35 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 25.87, 33.11, 35.94, 52.07, 85.75, 95.56, 126.19, 128.28, 128.50, 129.46, 133.89, 135.51, 163.88, 172.36; ESIMS *m/z* 304 (M⁺+H). Anal. Calcd for C₁₆H₁₇NO₅: C, 63.36; H, 5.65; N, 4.62. Found: C, 63.51; H, 5.81; N, 4.46.

Compound **5d**: (4 h, 63%); white solid, mp 123–125 °C; IR (KBr) 2984, 2909, 1643, 1616, 1585, 1537, 1445 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 1.36 (t, *J* = 7.2 Hz, 3H), 1.61 (s, 3H), 2.75 (d, *J* = 16.8 Hz, 1H), 2.94 (d, *J* = 15.6 Hz, 1H), 3.34 (d, *J* = 16.8 Hz, 1H), 3.51 (d, *J* = 15.6 Hz, 1H), 4.29 (q, *J* = 7.2 Hz, 2H), 7.31–7.44 (m, 5H), 7.59 (s, 1H), 12.45 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 14.23, 25.82, 33.16, 35.96, 61.16, 85.81, 95.75, 126.32, 128.23, 128.50, 129.46, 133.70, 135.57, 163.79, 172.07.

Compound **5e**: (5 h, 71%); white solid, mp 80–82 °C; IR (KBr) 2949, 1644, 1589, 1544, 1445, 1345 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.84 (t, *J* = 7.5 Hz, 3H), 1.94 (q, *J* = 7.5 Hz, 2H), 2.71 (d, *J* = 16.8 Hz, 1H), 2.89 (d, *J* = 15.6 Hz, 1H), 3.34 (d, *J* = 16.8 Hz, 1H), 3.54 (d, *J* = 15.6 Hz, 1H), 3.84 (s, 3H), 7.31–7.44 (m, 5H), 7.57 (s, 1H), 12.33 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 7.92, 30.99, 32.10, 34.03, 52.06, 89.39, 95.59, 126.11, 128.21, 128.50, 129.39, 133.77, 135.57, 164.07, 172.40.

Compound **5f**: (4 h, 66%); white solid, mp 94–96 °C; IR (KBr) 2954, 2869, 1651, 1621, 1593, 1542, 1438 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz) δ 0.84 (t, *J* = 7.2 Hz, 3H), 1.10–1.30 (m, 4H), 1.85–1.91 (m, 2H), 2.71 (d, *J* = 16.8 Hz, 1H), 2.89 (d, *J* = 15.6 Hz, 1H), 3.35 (d, *J* = 16.8 Hz, 1H), 3.54 (d, *J* = 15.6 Hz, 1H), 3.84 (s, 3H), 7.30–7.45 (m, 5H), 7.57 (s, 1H), 12.33 (s, 1H); ¹³C NMR (CDCl₃, 75 MHz) δ 13.68,

22.35, 25.45, 31.35, 34.46, 38.80, 52.06, 89.10, 95.63, 126.16, 128.21, 128.50, 129.38, 133.76, 135.59, 164.05, 172.41.

Synthesis of 6a (Typical procedure): To a stirred mixture of **5a** (144 mg, 0.5 mmol) in THF (2 mL) was added DBU (152 mg, 1.0 mmol) and the reaction mixture was heated to reflux for 5 h. After the usual aqueous extractive workup with ether and column chromatographic purification process (hexanes/ether, 10:1), we obtained **6a** as a white solid, 75 mg (62%). The other compounds were synthesized analogously and the spectroscopic data are as follows.

Compound 6a: (THF, 5 h, 62%); white solid, mp 80–82 °C; IR (KBr) 2858, 1631 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 2.25 (s, 3H), 2.60 (s, 3H), 3.98 (s, 2H), 7.11 (s, 1H), 7.18–7.30 (m, 5H), 7.39 (s, 1H), 12.46 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 20.57, 26.77, 35.07, 119.03, 126.01, 127.39, 128.37, 128.63, 128.90, 130.20, 138.05, 140.37, 158.35, 204.60; ESIMS m/z 241 ($\text{M}^+\text{+H}$). Anal. Calcd for $\text{C}_{16}\text{H}_{16}\text{O}_2$: C, 79.97; H, 6.71. Found: C, 79.91; H, 6.59.

Compound 6b: (THF, 11 h, 44%); white solid, mp 81–83 °C; IR (KBr) 2916, 1636, 1610, 1456 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 1.22 (t, $J = 7.2$ Hz, 3H), 2.25 (s, 3H), 3.01 (q, $J = 7.2$ Hz, 2H), 3.98 (s, 2H), 7.09 (s, 1H), 7.16–7.30 (m, 5H), 7.42 (s, 1H), 12.55 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 8.35, 20.62, 31.61, 35.11, 118.54, 125.99, 127.28, 127.74, 128.36, 128.91, 130.26, 137.72, 140.43, 158.34, 207.20. Anal. Calcd for $\text{C}_{17}\text{H}_{18}\text{O}_2$: C, 80.28; H, 7.13. Found: C, 80.42; H, 7.11.

Compound 6c: (THF, 29 h, 76%); yellow solid, mp 51–53 °C; IR (KBr) 3155, 2951, 1662, 1612, 1442 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 2.21 (s, 3H), 3.91 (s, 3H), 3.98 (s, 2H), 7.08 (d, $J = 2.1$ Hz, 1H), 7.15–7.30 (m, 5H), 7.51 (d,

$J = 2.1$ Hz, 1H), 10.87 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 20.41, 35.32, 52.16, 111.62, 125.97, 127.73 (2C), 128.34, 128.86, 129.33, 137.31, 140.46, 157.51, 170.91; ESIMS m/z 257 ($\text{M}^+\text{+H}$). Anal. Calcd for $\text{C}_{16}\text{H}_{16}\text{O}_3$: C, 74.98; H, 6.29. Found: C, 75.12; H, 6.43.

Compound 6d: (CH_3CN , 6 h, 71%); pale yellow solid, mp 52–53 °C; IR (KBr) 2928, 1666, 1614 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 1.40 (t, $J = 7.2$ Hz, 3H), 2.23 (s, 3H), 3.98 (s, 2H), 4.38 (q, $J = 7.2$ Hz, 2H), 7.07 (s, 1H), 7.16–7.30 (m, 5H), 7.52 (s, 1H), 10.96 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 14.21, 20.43, 35.33, 61.27, 111.88, 125.96, 127.64, 127.71, 128.34, 128.87, 129.30, 137.20, 140.52, 157.59, 170.54.

Compound 6e: (CH_3CN , 5 h, 47%); pale yellow solid, mp 31–33 °C; IR (KBr) 2952, 1667, 1613 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 1.17 (t, $J = 7.5$ Hz, 3H), 2.52 (q, $J = 7.5$ Hz, 2H), 3.92 (s, 3H), 4.00 (s, 2H), 7.12 (d, $J = 1.8$ Hz, 1H), 7.18–7.30 (m, 5H), 7.54 (d, $J = 1.8$ Hz, 1H), 10.89 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 15.68, 27.89, 35.45, 52.17, 111.69, 125.96, 126.52, 128.34, 128.85, 129.35, 134.29, 136.34, 140.48, 157.74, 170.96; ESIMS m/z 271 ($\text{M}^+\text{+H}$).

Compound 6f: (CH_3CN , 4 h, 56%); yellow oil; IR (CH_2Cl_2) 2954, 1674, 1612, 1442 cm^{-1} ; ^1H NMR (CDCl_3 , 300 MHz) δ 0.90 (t, $J = 7.2$ Hz, 3H), 1.25–1.35 (m, 2H), 1.47–1.57 (m, 2H), 2.48 (t, $J = 7.8$ Hz, 2H), 3.91 (s, 3H), 3.99 (s, 2H), 7.10 (d, $J = 2.1$ Hz, 1H), 7.15–7.30 (m, 5H), 7.52 (d, $J = 2.1$ Hz, 1H), 10.88 (s, 1H); ^{13}C NMR (CDCl_3 , 75 MHz) δ 13.89, 22.22, 33.69, 34.65, 35.45, 52.15, 111.64, 125.94, 127.12, 128.32, 128.83, 129.24, 132.95, 136.79, 140.49, 157.71, 170.95.